MX2021009979A - Variantes de fosfoglucoproteina de la matriz extracelular (mepe) y usos de estas. - Google Patents

Variantes de fosfoglucoproteina de la matriz extracelular (mepe) y usos de estas.

Info

Publication number
MX2021009979A
MX2021009979A MX2021009979A MX2021009979A MX2021009979A MX 2021009979 A MX2021009979 A MX 2021009979A MX 2021009979 A MX2021009979 A MX 2021009979A MX 2021009979 A MX2021009979 A MX 2021009979A MX 2021009979 A MX2021009979 A MX 2021009979A
Authority
MX
Mexico
Prior art keywords
mepe
osteoporosis
methods
bone mineral
mineral density
Prior art date
Application number
MX2021009979A
Other languages
English (en)
Inventor
Aris Economides
Aris Baras
Joshua Backman
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021009979A publication Critical patent/MX2021009979A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente métodos para tratar pacientes con densidad mineral ósea reducida y/u osteoporosis, métodos para identificar sujetos con un riesgo mayor de desarrollo de densidad mineral ósea reducida y/u osteoporosis, y métodos de diagnóstico de densidad mineral ósea reducida y/u osteoporosis en un sujeto humano, los cuales comprenden detectar la presencia de polipéptidos y moléculas de ácido nucleico de una variante de pérdida de función de una fosfoglucoproteína de la matriz extracelular (MEPE) en una muestra biológica del paciente o sujeto.
MX2021009979A 2019-02-18 2020-02-07 Variantes de fosfoglucoproteina de la matriz extracelular (mepe) y usos de estas. MX2021009979A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806939P 2019-02-18 2019-02-18
US201962862842P 2019-06-18 2019-06-18
PCT/US2020/017189 WO2020171979A1 (en) 2019-02-18 2020-02-07 Matrix extracellular phosphoglycoprotein (mepe) variants and uses thereof

Publications (1)

Publication Number Publication Date
MX2021009979A true MX2021009979A (es) 2021-12-10

Family

ID=69771167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009979A MX2021009979A (es) 2019-02-18 2020-02-07 Variantes de fosfoglucoproteina de la matriz extracelular (mepe) y usos de estas.

Country Status (11)

Country Link
US (1) US20200263251A1 (es)
EP (1) EP3927843A1 (es)
JP (1) JP2022520660A (es)
KR (1) KR20210136037A (es)
CN (1) CN113544285A (es)
AU (1) AU2020224073A1 (es)
CA (1) CA3130092A1 (es)
IL (1) IL285622A (es)
MX (1) MX2021009979A (es)
SG (1) SG11202108764SA (es)
WO (1) WO2020171979A1 (es)

Also Published As

Publication number Publication date
EP3927843A1 (en) 2021-12-29
AU2020224073A1 (en) 2021-09-16
IL285622A (en) 2021-09-30
AU2020224073A8 (en) 2021-10-07
KR20210136037A (ko) 2021-11-16
WO2020171979A1 (en) 2020-08-27
SG11202108764SA (en) 2021-09-29
CA3130092A1 (en) 2020-08-27
CN113544285A (zh) 2021-10-22
JP2022520660A (ja) 2022-03-31
US20200263251A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
BRPI0511838A (pt) implante, placa óssea, método para emendar um osso quebrado, e, sistema de monitoramento
MX2021009983A (es) Variantes del componente 1 de canales ionicos mecanosensibles de tipo piezo (piezo1) y usos de estas.
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
Tristaino et al. Effectiveness of psychological support in patients undergoing primary total hip or knee arthroplasty: a controlled cohort study
MX2021008797A (es) Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
EP3246708A3 (en) Troponins for predicting kidney failure in heart surgery patients
Asif et al. Management of thalassemia in Pakistan
WO2009043848A3 (en) Use of the serological assay of the cytokine b-lymphocyte stimulator (blys) for the diagnosis, prognosis and the screening of therapeutic efficacy in immune-related diseases including organ-specific autoimmune diseases and transfusion reactions
Killoran et al. Biomarkers for Huntington's disease: a brief overview
Günsche et al. The variation of arthroplasty procedures in the OECD countries: analysis of possible influencing factors by linear regression
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
MX2021009979A (es) Variantes de fosfoglucoproteina de la matriz extracelular (mepe) y usos de estas.
Itsubo et al. Electrophysiological responsiveness and quality of life (QuickDASH, CTSI) evaluation of surgically treated carpal tunnel syndrome
US8630808B2 (en) Estimation of diagnostic markers
WO2007071829A3 (en) Methods and means related to diseases
EP3862441A3 (en) Method for the early diagnosis of cancer by means of ddpcr analysis of mirna and protein markers in liquid biopsy
MX2022002880A (es) Ensayo basado en sangre para diagnosticar y tratar fosforilacion de tau especifica con base en el sitio.
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
Marks Physiological systems under pressure
Geleit et al. Biomarkers as predictors of inpatient mortality in fractured neck of femur patients
Liu et al. Serum concentrations of fibrinogen in patients with spinal cord injury and its relationship with neurologic function
Byers et al. Introduction to Osteogenesis Imperfecta
GB0713363D0 (en) Diagnosis and treatment of abnormal blood conditions
Hopper Long-term antibiotic therapy is just as effective as amputation for foot osteomyelitis in diabetics without peripheral arterial disease